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RESUMO/ABSTRACT 
Resumo  
A pneumonia nosocomial é uma infecção prevalente e associada com elevados 
custos e morbi-mortalidade. A maioria destes episódios ocorre em pacientes 
criticamente doentes em ventilação mecânica. Os biomarcadores, como a proteína C-
reativa, tem se mostrado uteis na avaliação da evolução dos pacientes, podendo se 
descrever padrões de resposta associados ao sucesso da terapia antimicrobiana e ao 
prognostico de paciente com pneumonia associada a ventilação mecânica. 
 Nesta tese, apresenta-se uma revisão da literatura abordando aspectos da 
fisiopatologia, diagnostico e manejo da pneumonia associada a ventilação mecânica. 
Além disso, é feita a análise do uso de biomarcadores em duas populações especificas 
de pacientes criticamente doentes (pacientes com doença critica cronica e pacientes 
idosos). Foram avaliados 405 pacientes com diagnostico clínico de pneumonia 
associada a ventilação mecânica. 
 Descreve-se que pacientes com doença critica crônica apresentam episódios de 
pneumonia associada a ventilação mecânica com pior prognostico do que pacientes 
que não apresentam doença critica crônica. Entretanto, esses achados não parecem 
associados a um comprometimento da resposta inflamatória, uma vez que nao houve 
diferença significativa nem nos níveis basais, nem na evolução dos níveis de proteína 
C-reativa comparando episódios de pacientes com doença critica crônica com aqueles 
sem esta condição, sugerindo que seu uso é válido nessa população de pacientes. 
Ainda, descreve-se a evolução dos pacientes com pneumonia associada a 
ventilação mecânica de acordo com a idade. A partir dos 65 anos, parece haver um 
efeito da idade na mortalidade dos pacientes com PAV. No entanto, não houve 
alteração na resposta da PCR ou na sua cinética nas primeiras 96h quando 
comparamos pacientes com diferentes faixas etárias a partir de um ponto de corte de 
65 anos, também sugerindo a validade do uso deste biomarcador nesta população de 
pacientes. 
Estes achados originais permitem que estudos futuros avaliem intervenções 
baseadas em biomarcadores em pacientes com pneumonia nosocomial levando em 
consideração estas populações especificas de pacientes não avaliadas previamente na 
literatura. 
 
Palavras chave: Medicina Intensiva; Pneumonia, Biomarcador; Proteina C-reativa, 
Ventilação Mecanica.  
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ABSTRACT 
 Nosocomial pneumonia is a prevalent infection associated with higher costs 
and worse outcomes. Most episodes occur in mechanically ventilated critically ill 
patients. Biomarkers, such as C-reactive protein, are useful to assess patients 
evolution, allowing identification of patterns associated with antimicrobial treatment 
success and prognosis in ventilator-associated pneumonia patients. 
 In this thesis, a literature review is presented evaluating aspects of 
pathopsysiology, diagnosis and management of ventilator-associated pneumonia 
patients. In addition, biomarker use in two specific populations (chronic critical 
illness and elderly) was assessed. Four hundred and five patients with ventilator 
associated pneumonia clinical diagnosis were evaluated.  
 Patients with chronic critical illness presented ventilator-associated pneumonia 
episodes associated with worse prognosis. However, these findings were not 
associated with a compromise of inflamatory response, assessed by comparison of C-
reactive protein basal levels and kinetis evolution in patients with and wihtout chronic 
critical illness, suggesting its use remains valid in this specific population. 
 Still, evolution of ventilator-associated pneumonia according to age is 
described. After 65 years old, our data suggest an effect of age on mortality in 
ventilator-associated pneumonia patients. However, no change in C-reactive protein 
basal levels, response or kinetics within 96h was found when comparing patients 
younger and older than 65 years old, also suggesting this biomarker usefulness in this 
specific population. 
 These original findings allow that future studies assessing intervention based 
on biomarkers evolution in patients with nosocomial pneumonia consider these 
specific populations, never assessed before in literature. 
 
Key words: Critical Care; Pneumonia; Biomarker; C-reactive protein; Mechanical 
ventilation  
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INTRODUÇÃO 
 
 A pneumonia nosocomial é a segunda infecção mais frequente no ambiente 
hospitalar, correspondendo a aproximadamente 15% destas e afetando de 0,5 a 2% 
dos pacientes hospitalizados (1). Cerca de 60% destes episódios ocorrem dentro de 
um ambiente de cuidados intensivos, onde é a infecção nosocomial mais comum, 
usualmente associada a ventilação mecânica. Tem uma prevalência variável, com 
taxas desde 6 até 50 casos por 100 admissões na UTI (2,3). Tal variabilidade se deve 
principalmente a dois aspectos: a presença de diferentes case-mix em diferentes 
unidades e a inexistência de critérios diagnósticos precisos que permitam um 
diagnóstico operacional acurado, tornando a subjetividade um aspecto importante na 
definição dos casos e nas decisões terapêuticas. Esta complexidade diagnóstica 
dificulta a comparação entre diferentes estudos e até mesmo estratégias de 
benchmarking baseadas na utilização das taxas de pneumonia associada a ventilação 
mecânica (PAV) como um marcador de qualidade assistencial (4,5).   
 O desenvolvimento de pneumonia nosocomial, e no ambiente de cuidados 
intensivos especificamente da PAV, tem morbidade significativa associada, 
prolongando o tempo de ventilação mecânica, bem como o tempo de permanência na 
UTI, com todos os custos associados a este prolongamento (6,7). A mortalidade 
atribuída a PAV ainda é um aspecto controverso na literatura. A mortalidade global 
nos episódios de PAV variam de 20 a 60%, refletindo em grande parte a gravidade da 
doença de base destes pacientes, a disfunção orgânica pré-existente ou instalada e 
especificidades da população estudada e do agente etiológico envolvido. Embora 
estudos mais antigos com uma metodologia mais simples (ex. caso-controle) (8,9) 
sugerissem um aumento de até 30% em média na mortalidade com o desenvolvimento 
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de PAV, estudos mais recentes, utilizando análise de desfechos concorrentes e análise 
causal, levando em consideração o tempo de aquisição da PAV bem como as relações 
complexas entre a gravidade da doença de base e o risco de desenvolver PAV, 
sugerem que tal impacto é superestimado e que a mortalidade atribuível estaria abaixo 
de 2% (10). Novamente, é provável que algumas características de populações 
específicas, bem como de agentes etiológicos específicos estejam sub-representadas 
nestas estimativas. 
 O diagnóstico de Pneumonia nosocomial à beira do leito leva em consideração 
uma combinação de achados clínicos, radiológicos e laboratoriais (1,11). Dados 
microbiológicos são utilizados como uma tentativa de refinar a acurácia diagnóstica, 
dada a baixa especificidade dos critérios clínicos isoladamente. Esses critérios 
incluem: 
- presença de infiltrado persistente novo ou progressivo OU consolidação OU 
cavitação; 
E 
- pelo menos dois desses critérios: febre (temperatura axilar acima de 38ºC), sem 
outra causa OU leucopenia (<4.000 cel/mm
3
) ou leucocitose (>12.000 cel/mm
3
) OU 
surgimento de secreção purulenta ou mudança das características da secreção ou 
aumento da secreção. 
 Ainda podem ser considerados fatores importantes a presença de 
comprometimento funcional (hipoxemia, com piora da relação pressão parcial de 
oxigênio/fração inspirada de oxigênio - PO2/FiO2), o aumento nos níveis de  
biomarcadores, confusão mental ou surgimento de sepse grave/choque séptico. 
  A PAV é considerada com confirmação microbiológica se está presente pelo 
menos um dos critérios laboratoriais: hemocultura positiva, sem outro foco de 
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infecção aparente OU cultura positiva do líquido pleural OU cultura do lavado 
broncoalveolar ≥104 UFC/mL ou do aspirado traqueal ≥106 UFC/mL OU exame 
histopatológico com evidência de infecção pulmonar OU antígeno urinário ou cultura 
para Legionella spp. OU outros testes laboratoriais positivos para patógenos 
respiratórios (sorologia, pesquisa direta e cultura). Na ausência, de uma dos critérios 
microbiológicos, é feito o diagnóstico de PAV clinicamente definida (1,11). 
 Uma tentativa de tornar o diagnóstico mais objetivo inclui o uso de um escore 
clínico - CPIS, entretanto não há um claro benefício na literatura no uso sistemático 
deste escore, como confirmação, mas seu valor preditivo negativo foi usado em um 
ensaio clinico para suspensão precoce do tratamento antimicrobiano em pacientes 
com suspeita de PAV sem piora no desfecho clinico. Escore acima de 6 pontos é 
sugestivo de pneumonia(12). 
 
USO DE BIOMARCADORES  
 
 Diversos biomarcadores foram avaliados como ferramentas para auxiliar no 
diagnóstico de pneumonia. Inclui-se entre eles proteína C-reativa (PCR), 
procalcitonina (PCT), soluble-triggering receptor expressed on myeloid cells (s-
TREM), interleucinas 8, 9 e 10 (IL8, IL6, IL10), fator de necrose tumoral (TNF-alfa), 
entre outros.  Na ausência de um padrão-ouro seria mais prudente o uso integrado de 
todas as variáveis clínicas disponíveis ao invés de limitar a uma única variável a 
definição do diagnóstico. 
 O uso de biomarcadores séricos como PCR ou PCT como fatores determinantes 
do inicio de tratamento empírico e, portanto, do diagnóstico foi avaliado em diversos 
estudos e não foi possível determinar um ponto de corte  adequado, nem uma 
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estratégia segura que pudesse ser incorporada a prática clínica(13,14). 
 A PCR foi identificada em 1930 pela primeira vez no soro de pacientes com 
pneumonia pela capacidade de precipitar frações de polisacarídeo, chamadas de 
fração C, do Streptococcus pneumoniae (15). Pertence a família das pentraxinas, 
proteínas que se mantiveram preservadas ao longo da evolução dos vertebrados, 
sugerindo seu papel na resposta imunológica inata. Juntamente com o complemento 
tem ação na opsonização promovendo fagocitose bem como representa estímulo a 
ação citotóxica das células NK e ativação neutrofílica(16). Além disso parece ter ação 
antibacteriana direta através da ligação a parede celular bacteriana (16). A PCR é 
sintetizada predominantemente no fígado e apresenta boa correlação com outros 
marcadores como IL6 e TNF-alfa, que tem ação reguladora de sua secreção.  
 Os níveis de PCR se elevam sempre que houver um processo inflamatório em 
evolução e sua concentração depende da intensidade do estímulo. Os níveis não são 
alterados por terapia de substituição renal, sendo influenciados apenas por 
intervenções que interfiram no processo inflamatório que gerou a alteração (17). Os 
níveis de PCR encontram-se elevados na maioria dos quadros infecciosos. Infecções 
bacterianas, fúngicas invasivas e alguns quadros virais estão associados com 
aumentos significativos no nível sérico de PCR, mesmo em pacientes com deficiência 
imunológica(18). A secreção de PCR costuma iniciar em 4-6h após o estímulo inicial, 
dobrando em 8h e atingindo o pico de concentração em 36-48h. Uma vez cessado o 
estímulo a PCR cai rapidamente e sua meia-vida estimada é de cerca de 18-20h 
(16,17). 
 O uso de PCR foi avaliado em diversos estudos em pacientes com sepse e 
pneumonia. Tentativas de identificar pontos de corte que auxiliem no diagnostico de 
pacientes com sepse não permitiram estabelecer uma abordagem definitiva, não sendo 
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recomendado o uso destes biomarcadores no processo de tomada de decisão para o 
inicio de tratamento antimicrobiano. A variabilidade individual e diferenças nas 
respostas sugeriu o uso da PCR como uma marcador de evolução de pacientes com 
sepse. 
  A avaliação da evolução dos pacientes com sepse inclui o uso de parâmetros de 
resposta clínica, como resolução da febre, leucocitose e uso de biomarcadores, como 
proteína C-reativa e procalcitonina, que permitem avaliar a evolução clinica. No 
mínimo 48 a 72 horas são necessárias para que os parâmetros de melhora clínica 
sejam avaliados. A diminuição da febre, a redução na quantidade e purulência da 
secreção brônquica e a redução na contagem de leucócitos são critérios importantes 
de resposta clínica. A melhora da oxigenação possibilitando a redução da fração 
inspirada de oxigênio (FiO2), a redução das pressões e a estabilidade hemodinâmica 
são fortes indícios de resposta terapêutica.  Além disso, o padrão de resposta clínica, 
avaliado a partir da variação de biomarcadores como PCR e procalcitonina parecem 
se correlacionar com adequação da antibioticoterapia empírica, bem como com o 
prognóstico destes pacientes (19-23).  
  Em pneumonia nosocomial, Povoa et al. (19) avaliou 47 pacientes com VAP e 
descreveu que queda >0,4 vezes no quarto dia de evolução está associado com  
melhor prognóstico, com melhor performance comparado com evolução de febre e 
leucograma, sem influência da presença de infecção prévia, presença de síndrome de 
distresse respiratório do adulto ou motivo da ventilação mecânica. Além disso, uma 
associação entre a queda nos niveis de PCR com antibioticoterapia empírica 
adequada, sugerindo o uso deste biomarcador para avaliação da evolução e resolução 
clinica de um quadro infeccioso pulmonar grave. Este achado foi confirmado em 
estudos posteriores (20-23). Algumas populações especificas foram avaliadas como 
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pacientes HIV, hepatopatas, neutropenicos ou com câncer (18, 23-25). Entretanto, em 
algumas populações especificas, cuja prevalência tem aumentado nas unidades de 
terapia intensiva como pacientes doença critica crônica ou persistente e idosos, o uso 
de PCR ainda não foi avaliado. 
 Nos estudos apresentados nesta tese, procuramos explorar algumas das 
lacunas na literatura, apresentando uma revisão extensa da literatura sobre a 
pneumonia nosocomial no paciente ventilado e avaliando o uso de biomarcadores em 
duas populações especificas de pacientes criticamente doentes (pacientes com doença 
critica crônica e pacientes idosos). 
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JUSTIFICATIVA 
 
 O uso de biomarcadores como a PCR para auxiliar na avaliação da evolução 
de pacientes com PAV esta demonstrado na literatura. Quedas significativas nos 
níveis deste biomarcador estão associados com melhor prognóstico, assim como com 
a adequação do tratamento antimicrobiano. Entretanto, a heterogeneidade dos 
pacientes criticamente doentes, torna muitas vezes necessária a avaliação das 
estratégias utilizadas em alguns subgrupos, pois eventualmente o comportamento dos 
diferentes marcadores biológicos pode variar de maneira significativa. 
 Neste documento, a estratégia de usar biomarcadores para estudar a evolução 
de pacientes com PAV é avaliada em duas populações especificas: pacientes idosos e 
pacientes com doença critica crônica. Esta informação é relevante cientificamente 
pois permitirá que intervenções desenhadas baseadas na variação dos biomarcadores 
possam ser avaliadas também nestas populações. Potenciais diferenças no 
comportamento dos biomarcadores nestas populações que forem identificados neste 
estudo podem comprometer a utilidade do uso de biomarcadores ou indicar ajustes na 
avaliação nos pacientes com doença critica crônica e idosos.  
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OBJETIVOS 
Geral 
1) Descrever a epidemiologia, aspectos microbiológicos e resposta clinica, baseada na 
evolução de proteína C-reativa nos pacientes com pneumonia nosocomial admitidos a 
unidade de terapia intensiva, com ênfase em populações especificas pre-definidas. 
Específicos 
1) Avaliar o uso da proteína C-reativa como marcador de evolução em pacientes 
com doença crítica crônica e  descrever a epidemiologia dos episódios de PAV 
nesta população. 
2)  Avaliar  proteína C-reativa como marcador de evolução em pacientes idosos, 
bem como descrever a epidemiologia dos episódios de PAV nesta população 
específica. 
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ASPECTOS ÉTICOS 
 O autor garante confidencialidade quanto aos dados obtidos, assegurando que 
foram usados com fim único e exclusivo da pesquisa clínica e foram analisados de 
modo agregado, preservando a identidade dos participantes, garantindo a 
anonimização. Foram observadas as recomendações da Resolução número 196 de 
10/10/1996 – Conselho Nacional de Saúde para Pesquisa Científica em Seres 
Humanos. Zelou-se pela beneficência, comprometendo-se com o máximo de 
benefícios e o mínimo de danos e riscos, e pela não-maleficência, garantindo que 
danos previsíveis serão evitados. Os procedimentos foram realizados rotineiramente 
na UTI e faziam parte do cuidado habitual dos pacientes. 
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ABSTRACT 
 
Lower airway infections in mechanically ventilated patients are a frequent cause of 
antibiotic prescriptions in the ICU setting. They present in the form of severe sepsis or 
septic shock in intubated patients. Purulent respiratory secretions are required for 
diagnosis, but the differential diagnosis between pneumonia and tracheobronchitis is 
not easy. Both presentations are associated with prolonged duration of mechanical 
ventilation and ICU stay, providing rationale for antibiotic treatment initiation. 
Quantitative cultures might help to differentiate colonizers from true pathogens, being 
Staphylococcus aureus and Pseudomonas aeruginosa of great concern. Key 
management issues are the following: What is the pathogen, which is the initial 
empirical antibiotic choice, and decisions depending on the resolution pattern.   
 
 
 
Words: 110
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Introduction 
In the point prevalence EPICII study that was conducted in 1,265 intensive care units 
(ICUs) from 75 countries worldwide,
1
 51% of adult ICU patients were infected and 
the respiratory tract (RT) was the focus of infection in 64% of the cases.
1
 In the 
medical ICU, airway infections in intubated patients are the main reason for antibiotic 
prescription. Since there is no gold standard for the diagnosis of RT infections in 
intubated patients 
2
, prescription of antibiotics for patients with purulent respiratory 
secretions is a common clinical practice in the ICU setting. This article reviews 
ventilator-associated respiratory infections (VARI) in adult patients, placing particular 
emphasis on aspects of diagnosis, microbiological etiology and management. 
 
The clinical challenge of respiratory infections in ventilated patients 
The presentation of the patient in the vignette is suggestive of lower respiratory 
infection, presenting progressive hypoxemia and fever that is in contrast with the 
sudden onset of rigors and temperature rise of bloodstream infections.  
In our view, the low sensitivity and specificity of the current diagnostic criteria is the 
most important problem in the assessment and diagnostic approach of mechanically 
ventilated patients with suspected lower airway infections.
3
 The clinical syndrome 
definition based on VARI clinical presentation is a challenge for clinicians. Since the 
criteria include many subjective components (such as chest X-ray [CXR], assessment 
of respiratory secretions, and even auscultation) the inter-rater variability for 
identifying VAP is high.
4,5
 A recent prospective survey that was conducted in a 
nationally representative group of US hospitals asked the participants to classify 
standardized vignettes of possible cases of VAP as pneumonia or no pneumonia. This 
study reported that the agreement among hospitals about classification of cases as 
 26 
ventilator-associated pneumonia or not was nearly random, highlighting the 
limitations of the current definitions.
6
  
The clinical pulmonary infection score  (CPIS) was created to predict the pre-test 
probability of pneumonia.
7
 It combines information on body temperature, volume and 
appearance of tracheal secretions, CXR, WBC count, oxygenation, and tracheal 
aspirate culture.
7  
Many randomized clinical trials have used the CPIS score to 
identify patients with pneumonia as it allows an objective assessment of clinical 
variables for pneumonia diagnosis
8,9
. Unfortunately, despite of using objective data as 
WBC count or oxygenation, CPIS also includes variables that are either subjective or 
retrospective, such as CXR findings and microbiological data what might compromise 
its utility in some sub-groups (e.g. SDRA patients). We consider that individual 
diagnostic decisions should not be made based on scores. Diagnostic scores are 
helpful for providing probabilities for comparisons between groups, but seems not 
appropriate for the assessment of the probability of pneumonia in individual patients. 
Differentiate VAP and VAT based only on clinical signs might be a difficult task at 
bedside. The cut-off points for colonization, tracheobronchitis and pneumonia in MV 
patients have not been conclusively defined, and there is also a clear need to assess 
vasopressor requirement and complications such as the effect of the respiratory 
infection on oxygenation. The US Centres for Disease Control and Prevention (CDC) 
diagnosis of ventilator-associated tracheobronchitis (VAT) is based on the absence of 
CXR infiltrates and the presence of signs consistent with respiratory inflammation 
along with at least 1 microbiologic criterion.
4 
However the lack of objectivity and the 
inherent variability in the interpretation of CXR in MV patients makes it difficult to 
take decisions based on CXR. Dallas and colleagues reported a median onset of VAT 
7.5 days after intubation and initiation of MV compared with 5 days of VAP, 
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suggesting that VAT and VAP might be two distinct entities, and that VAT is not 
necessarily a precursor of VAP, although a high percentage of patients initially 
diagnosed as VAT evolved to VAP. In addition, it suggests antibiotic use might be an 
important factor influencing whether VAT progresses to VAP. 
10
 Pathophysiological 
aspects of VAT and VAP correlation are proposed in figure 1 and are also discussed 
in VAT management section. 
Beyond clinical differences between VAT and VAP, a pilot translational study 
comparing gene expression profiles in VAP and VAT identified that 5,595 genes 
expressed differently in the pre-infection period.
11
  A significant depression of the 
complement system signalling pathway was identified in the VAP group, along with a 
depression of cAMP and calcium signalling pathways during the pre-infection 
phase.
11 
  
 
Epidemiological features 
 
The epidemiology of respiratory infections varies, depending on whether the patient is 
mechanically ventilated with a tracheostomy or an endotracheal tube. The role of the 
biofilm is important in tracheostomized patients.
12,13
 Aspiration constitutes the main 
pathophysiological event. Avoiding an artificial airway is the best method of 
prevention. In contrast with community-acquired pneumonia (CAP) episodes, 
respiratory infections in MV patient are heterogeneous. Poor comparison can be 
established when a patient with intra-abdominal surgery is compared with another 
who underwent cardiac surgery or trauma. Moreover, medical patients are a different 
subset, and when VAP develops as a complication of severe CAP,  P. aeruginosa is 
the most frequent organism. 
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While the attributable mortality of VAP is controversial, it certainly does prolong 
mechanical ventilation and the length of stay in the ICU.
 14
 In a recent metanalysis,
15
  
the overall attributable mortality of VAP was estimated to be 13%.
 
Admission 
diagnosis, age, causative pathogens and adequacy of therapy are also influencing 
outcomes.  Higher attributable mortality rates were reported in surgical patients and 
patients with mid-range severity-of-illness at admission, whereas attributable 
mortality close to zero was reported in trauma, medical patients, and patients with low 
or high severity-of-illness scores.
15
 However, there is a huge variability on incidence-
rate and attributable mortality in different studies
16-22
. Data from low-income and 
developing countries suggest the incidence-rates and attributable mortality might be 
higher 
16-22
 .  
A particular challenge is the development of pneumonia in the postoperative period of 
lung transplantation because its presentation may overlap with acute rejection that 
requires an opposite therapeutic approach (increase versus decrease 
immunosuppressors).
23
 Interestingly, Riera and colleagues reported that episodes of 
tracheobronchitis doubled episodes of pneumonia in this subset of patients.
23 
Pneumonia was related with increased in-hospital death (42.9% vs 11.5%; p=0.01), 
while tracheobronchitis was not related to this increased mortality (14.0% vs 14.7%; 
p=0.9).
23
 In a prospective observational study of 2,436 patients from 27 ICUs in nine 
European countries,
24
 mortality of VAP was 73% lower in trauma compared to non-
trauma patients.  In addition, Melsen and colleagues reported that VAP development 
decreased the daily probability of discharge from the ICU by 26%, indicating that the 
disorder extends the length of ICU stay.
25
 
In addition, variability on VAP rates might be due to lack of a diagnostic gold 
standard. The standard definition used to measure VAP rates is based on several 
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nonspecific clinical signs with the addition of microbiologic criteria aiming to 
improve specificity, but may be severely limited by lack of sensitivity and specificity 
of current criteria
14
. Also, differences between surveillance strategies and the clinical 
definition of VAP are crucial for understanding such variability. It impacts on 
appropriate assessment of prevention studies, as lower rates might be associated to 
different criteria in subjective aspects of diagnosis. An attempt to design a simple, 
objective surveillance definition for ventilator-associated complications (VAC) was 
presented by Klompas and colleagues, which
 
shifted the focus of surveillance from 
pneumonia alone to complications of MV,
26 
but impact on clinical practice of 
adopting such new criteria is not available.  
 Our view is that prevention trials and recommendations should no longer focus on 
VAP rates. Only measures associated with improved outcomes (particularly lower 
duration of MV) and reduced costs should be implemented. A recent Spanish 
multicenter cohort study have reported that full VAP prevention care bundle 
compliance was associated with an incidence risk ratio of VAP of 0.78 (95% CI 0.15-
0.99), as well as with a reduction of both median ICU length of stay (LOS) from 10 to 
6 days and MV duration from 8 to 4 days.
27
 Key interventions were oral care, 
maintaining pressure of the cuff, hand hygiene before artificial airways manipulation 
and strategies to avoid hyper-sedation. Prolongation of ICU stay is associated with 
increased (preventable) healthcare costs, as it was reported in a large matched cohort 
study,
28 
 and emphasizes the interest of giving priority to prevention measures, that 
have demonstrated potential costs’ reduction, (rather than rates’ reduction).  
 
Pathogens 
 30 
Less than ten organisms are implicated in the vast majority of VARI cases and it 
should be noted that a significant percentage are polymicrobial infections.
29 
In the 
recent years a shift in the pattern of respiratory pathogens have been towards Gram-
negative infections. The EUVAP study 
29
  identified Staphylococcus aureus and 
Pseudomonas aeruginosa as the most commonly isolated pathogens in VAP.
29
 Core 
organisms, such as methicillin susceptible S. aureus (MSSA), Haemophilus 
influenzae or Streptococcus pneumoniae are common causes of early-onset VAP in 
trauma patients, but VAP improves quickly (within three days) when adequate 
therapy is promptly started. A recently published secondary analysis of the EUVAP 
study reported that elderly ICU patients with VAP had increased rates of 
Enterobacteriaceae compared to younger age groups.
30
 Table 1 details the top three 
pathogens of VAP reported in six studies published during the last decade.
29,31-35
 
Figure 2 depicts the median onset of VAP by pathogen.  
 
Antibiotic resistance 
Nosocomial infections are commonly caused by ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species).
36
  Sandiumenge and colleagues 
reported S. aureus, P. aeruginosa and A. baumannii as the top three pathogens.
37
 
Enteroccus sp. and Candida sp, on the other hand, should be interpreted as oral 
contaminants. The risk of MDR pathogens causing VAP is mainly determined by 
comorbidity and prior exposure to more than two antibiotics. The increased mortality 
of VAP caused by MDR as compared with non-MDR pathogens is explained by more 
severe comorbidity and presence of organ failures
38
.  Resistant ESKAPE VAP 
mortality was double (RR, 2.25; 95% CI, 1.67-9.48) compared with the mortality of 
 31 
the remaining patients with VAP.
37 
Therefore, we will focus the discussion on MRSA 
and P.aeruginosa that constitutes a major concern, in terms of both outcomes and 
costs. Emergence of extended spectrum beta lactamases (ESBL) or Klebsiella 
pneumoniae carbapenemases (KPC) is of concern between Enterobacteriaceae, but 
these resistant pathogens are more frequently involved in extra-pulmonary infections. 
Also, we will discuss briefly A.baumannii, which is endemic in some ICUs. 
Severity-of-illness seems not to affect the etiology of VAP, therefore, risk factors for 
multi-drugs resistance (MDR) rather than the severity-of-illness should guide the 
initial empirical antibiotic therapy.
39
 On the other hand, it has been reported that 
patients with higher severity scores and septic shock at onset of pneumonia had 
significantly lower survival and higher systemic inflammatory response.
39
 In relation 
to VAP caused by MRSA, it is interesting to note that variables influencing decisions 
for anti-methicillin resistant S. aureus (MRSA) empiric prescription differ from risk 
factors.
40
 Factors associated with MRSA VAP development include prior antibiotic 
exposure, prolonged hospitalization, underlying COPD and steroid use.
41
 On the 
contrary, age younger than 25 years and neurologic impairment, such as head trauma, 
were associated with methicillin-susceptible strains. It is crucial to highlight that the 
baseline prevalence in a specific ICU should be to be taken into consideration before 
choosing the initial empirical antibiotic therapy on pneumonia suspicion. Bacteraemic 
VAP is independently associated with MRSA and mortality.
42
 Moreover, mortality is 
higher for MRSA versus methicillin-susceptible S.aureus (MSSA) ICU infections; a 
secondary analysis of the EPIC II study reported that MRSA was independently 
associated with an almost 50% higher likelihood of hospital death compared with 
MSSA infection.
43
    
 32 
In regards to MRSA VAP treatment, there is a lot of controversy in relating to 
glycopeptides’ versus linezolid’s use, that has been fueled by the vancomycin’s 
minimal inhibitory concentration (MIC) creep, the poor alveolar penetration of 
vancomycin, the potential adverse events, linezolid’s cost and the high rate of poor 
clinical resolution of MRSA VAP
44
. Regarding  resolution, MRSA VAP traditionally 
has poor resolution and half of the patients need MV for more than 3 weeks after 
pneumonia onset.
44 
Vidaur et al reported that the resolution of MRSA VAP was 
associated with longer need for respiratory support compared to VAP due to other 
pathogens, regardless of the appropriateness of initial antibiotic therapy.
44
 
Interestingly, a prospective, double-blind, controlled, multicenter trial involving 
hospitalized adult patients with nosocomial MRSA pneumonia reported that, although 
60-day mortality was similar between linezolid and dose-optimized vancomycin, 
clinical response was significantly higher with linezolid.
45
 Moreover, acute kidney 
injury has been associated with vancomycin’s use in patients with glomerular 
filtration rate (GFR) above 50 ml/min (18.8% for vancomycin vs. 5.6% for 
linezolid).
45
 This study however, is not definite as presents some potential biases, 
including trend to unequal comorbidities distribution between groups and bacteremia 
46
 . A practical approach that we suggested was to use linezolid in patients with 
immunosuppression, concomitant administration of nephrotoxic drugs, vasopressors, 
severe sepsis or in elderly patients, and to administer glycopeptides in the absence of 
these factors. 
Further research is required in adjunctive therapy, neutralizing virulence factors 
(alginate, pantovalentin leukocidine or alfatoxin) to improve outcomes and minimize 
injury.  
 33 
 With respect to P. aeruginosa, over the last decade an increase in the frequency of 
MDR P. aeruginosa (MDR-PSA) strains has been recorded.
47 
 In the ICU, MDR-PSA 
represents a major issue regarding infections management, especially VAP.
48
 Patients 
at risk of PSA infection should receive combination therapy with two agents from 
pneumonia onset, due to the probability of initial wrong therapy, which was 
associated with statistically significant higher mortality.
49
 However, when susceptible, 
an agent has comparable outcomes than two, and simplifying to a single agent can be 
implemented after susceptibility is available.
49
 For empirical therapy choice, 
prescribers should bear in mind the factors reported to be associated with isolation of 
MDR-PSA. These factors include admission from chronic care facilities,
50 
advanced 
age, diabetes, prolonged hospitalization,
50-52
 using invasive devices,
50,53,54
 recent 
surgery,
52 
and predominantly prolonged ICU stay, prolonged ventilation periods, and 
higher severity-of-illness scores.
54-56
 It has been reported that Candida spp airway 
colonization may promote pneumonia development, especially when caused by PSA, 
perhaps linked to the biofilm environment in the artificial airway.
57-60
 In episodes with 
clinical suspicion of VAP, Candida spp airway colonization was associated with 
increased mortality risk (OR:1.72).
58 
Moreover, yeasts have been reported as an 
independent risk factor for identification of MDR microorganisms (OR: 1.79). Further 
research is needed to understand if Candida airways colonization should be a variable  
influencing selection of VAP empiric therapy.
58 
 Cross-infection also may contribute 
to emergence of MDR-PSA strains.
54, 61-
Indeed, a key role for acquisition of MDR 
strains are prior antibiotic exposure.
61-63 
 Indeed, aminoglycosides exposure has been 
identified as risk factor;
50
however, other reports also identified the importance of anti-
pseudomonal cephalosporins,
50, 64
 fluoroquinolones (levofloxacin more than 
ciprofloxacin), 
52, 65,66 
and carbapenems, 
53,67
 It has been reported that imipenem might 
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have the greatest potential for MDR strains selection,
65
 whereas ertapenem does not 
induce carbapenem resistance to Pseudomonas strains.
62
 Prior treatment with anti-
pseudomonal penicillin/β-lactamase inhibitor combinations does not seem to increase 
isolation of MDR organisms.
66
  However, antibiotic therapy is not the only factor 
associated with the acquisition of MDR organism; a study of meropenem high-level-
resistant Pseudomonas strains reported an association between factors associated with 
higher severity and MDR strains, but failed to identify prior antibiotic exposure.
68
 
Implications of MDR-PSA infection, particularly respiratory infection, remain 
controversial. In 2006, it was reported that infection by MDR-PSA was associated 
with increased mortality (OR: 4.4) and hospital stay (HR: 2.0), when compared with 
controls.
50
 However, further reports suggested that MDR per se does not directly 
affect outcomes, being associated with factors related with MDR strains isolation. 
69,70 
Presence of organ dysfunction (OR= 10.4),
55
 more comorbidities and inappropriate 
empiric antibiotic therapy increased mortality (RR: 1.59), ICU and mechanical 
ventilation periods (at least 4 days) and hospital length of stay (13 days).
47
  
Piperacillin-resistance does not influenced outcomes in episodes of VAP.
69,70
  
Interestingly, recent research has emphasized the contribution of virulence factors in 
P.aeruginosa pneumonia. Quorum sensing and biofilm formation
71
 have been studied. 
These data suggest that type III secretion system (TTSS) encoded by PSA might play 
a substantial role. The needle-like TTSS mechanism allows bacteria to inject toxins 
directly into cytoplasm of cells’ host. Therefore, toxins are not exposed extra-
cellularly, evading direct recognition by the host immune system.
72 
These findings 
fueled the hypothesis than failure to eradicate Pseudomonas sp in pneumonia might 
be due to the TTSS. In pneumonia caused by P.aeruginosa, despite appropriate 
antimicrobial treatment, above 50% of the strains expressing at least one type of 
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TTSS protein (TTSS+) were recovered one week later. In contrast, eradication was 
documented in all episodes caused by TTSS- strains.
73 
The group leaded by Rouby, in 
a retrospective cohort of 143 patients with P.aeruginosa VAP, reported that O6 and 
O11 were the most prevalent strains. Moreover, mortality tended to be worse with 01 
or 011 serotypes and better with 02 or 06 serotypes.
74
 Moreover, clones exhibiting 
ExoU, one of the toxins secreted by the TTSS were frequently serotyped as O11, in 
contrast with serotype O6 strains, which were often associated with a negative exo U 
serotype.
75,76 
These findings highlight the importance of immunomodulatory 
adjunctive therapy in the future management of severe pneumonia.
77 
Elective P. 
aeruginosa vaccination in patients at high risk of late onset pneumonia represents 
another future way of prevention that warrants priority research. 
 
Acinetobacter baumannii is a non-fermentative Gram-negative bacilli (GNB) that has 
caused large outbreaks in contaminated ICUs. Compared with P aeruginosa, 
A.baumannii has different risk factors and lacks virulence factors. Independent risk 
factors for A.baumannii pneumonia in intubated patients include ARDS, head trauma, 
large-volume pulmonary aspiration,
78
 presence of tracheostomy,
79 
and prolonged ICU 
stay.
80 
Prolonged antibiotic course is a frequent risk factor for A.baumannii infections. 
Presence of a resistant phenotype that often involves carbapenems is of great concern.  
For carbapenem resistant strains, high doses of nebulized (aerosolized) colistin has 
been associated with good resolution and shorter periods of hospitalization.
81 
It has 
been claimed that the high doses of colistin can be delivered by nebulization without 
significant systemic exposure because of the fact that, even in the presence of severe 
lung infection, colistin does not easily cross the alveolar-capillary membrane.
81 
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Management Strategies  
Management Strategies of VAP 
The priority in pneumonia management is to avoid any delays in the administration of 
adequate antibiotics; inadequate treatment increases mortality and, in survivors, it 
increases healthcare costs. The use of broad-spectrum antibiotics as initial empirical 
has been advocated, however academics have concerns on resistance emergence. 
Indeed, the most effective strategy against resistance development should be based on 
prompt and unequivocal killing of the microbes and thereby defeating resistance 
before it starts (‘dead bugs don’t mutate’). In addition, the de-escalation strategy that 
allows the use use of broad-spectrum antibiotics as initial empirical, maximizing the 
odds to an appropriate antibiotic therapy associated with a early de-escalation, using a 
more strict-spectrum coverage after pathogen identification, minimizing exposure and 
risk for resistance emergence, have demonstrated benefit on clinical outcomes in 
ventilated patients. 
82,83
 The ‘right first time’ concept and short duration of therapy 
whenever possible, is the ‘two-steps’ strategy for VAP management.  
There is controversy regarding the best diagnostic method for VAP (invasive versus 
non-invasive sampling techniques).  A meta-analysis by Shorr and colleagues 
concluded that the use of invasive strategies did not alter mortality, but it affected 
antibiotic utilization, leading to modifications in the antibiotic regimen in more than 
half of patients.
84 
On the other hand, findings from Canadian Critical Care Trials 
Group study showed no difference in clinical and microbiolgical outcomes comparing 
an invasive and non-invasive diagnostic approach, suggesting endotracheal aspirate 
might be as effective as bronchoalveolar lavage for etiological diagnosis in VAP.
 85
 
Nevertheless, using quantitative culture technique might help to evaluate probability 
for colonization or infection, although no unequivocal cut-off could be found.
 86
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The optimal length of treatment has not been conclusively established, but in the EU-
VAP study,
40
 a large European multicentre cohort, standard of care was an 8-day 
antibiotic regimen, according to current recommendations 
87
. The EU-VAP study 
listed the causes of antibiotic prescription for intubated patients in Europe, including 
reasons for anti-MRSA prescription. Further studies are now required to evaluate 
more recently devised treatment strategies and their impact on emerging resistance.  
Careful antibiotic monitoring is recommended in the ICU setting, but it is not known 
which monitoring practices are associated with benefits. In fact, the real impact of 
stewardship on the emergence of resistance and on patients’ outcomes is still to be 
established, but it seems that changing our practices to individualize management, 
avoid homogeneous selective pressure and employ the entire potential of our 
antimicrobial choices are useful strategies to escape the adverse consequences 
associated with the emerging resistance 
88
. 
 
Management Strategies of VAT 
More controversial is the use of antibiotics in VAT. In a recent survey,
89 
only the 
24.3% of prescribers routinely prescribed antibiotics for VAT; conversely, 26% 
considered that VAT should not be treated with antibiotics, whereas only 24% 
indicated a preference for an antibiotic course lower than 7 days.
89 
Nseir and 
colleagues on the other hand, reported lower mortality rates and more MV free-days 
when VAT was treated with IV antibiotics (45% of the cohort were COPD patients).
90 
Palmer and colleagues  conducted a double-blind, randomized, placebo-controlled 
study, reporting decrease of VAP development rates, faster weaning,  reduced use of 
systemic antibiotics, and reduce of bacterial resistance when nebulized antibiotics 
were administered for VAT.
91 
Dallas and colleagues reported that patients diagnosed 
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with VAT had similar outcomes to those with VAP, suggesting that administration of 
antimicrobial therapy might be appropriate for VAT.
10
 Consistent reports of increased 
length of ICU stay in VAT due to prolonged MV need, provide a strong rationale for 
antibiotic administration. The duration of targeted VAT treatment has not been 
established, but VAT may respond to shorter courses.
92
Further research is warranted 
to identify the subgroup of patients with VAT that would benefit from antimicrobial 
treatment and the subgroup that could safely have antimicrobial therapy withheld or 
limited.  
 
Key issues for management of VAP and VAT  (Figure 3) are the following: a) 
Identification when to start an antibiotic; b) what microbiologic test can be of help to 
guide antibiotic prescriptions, being advisable to perform quantitative respiratory 
cultures of a high quality respiratory specimen; c) What organism should be covered, 
based on direct staining and the presence of potential risk factors; d) What initial 
agent should be prescribed and at what dosage, based on baseline susceptibilities, 
patient’s conditions and prior antibiotic exposure; e) duration of therapy.  
The currently standard on duration of antibiotic therapy for VAP is one week, 
although patients with core pathogens present quick resolution and might benefit from 
even ultra-short courses. On the other hand, in cases of P. aeruginosa VAP that 
receive inappropriate initial treatment or in cases of MRSA VAP, the resolution is 
usually delayed and more than 10 days of antibiotics are required.
44
 Improvement in 
oxygenation and defervescence occurs within three days in the majority of patients. 
Assessment of the delta value of a biomarker may contribute to more objective 
decisions, but increases costs.
93 
Resolution of CXR, WBCs count or clearance of 
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respiratory secretions does not help.
94 
In VAT, at present, there is no evidence that 
can support an objective decision to prolong therapy. 
Areas of uncertainty 
A long-standing problem in ICU care is the differential diagnosis between the 
inflammatory response and the infection. In many cases, the challenge is to establish 
whether bacteria are merely colonising the patient or whether they are in fact the 
cause of disease. There are two main issues here. First, how can we conclusively 
determine that the bacterial growth in the respiratory tract sample is the cause of the 
inflammatory response in a ventilated patient? Second, how can we establish that the 
microorganism isolated from an upper airway sample is the cause of the disease in the 
lower airway?  
 
The biomarkers required for pre-emptive treatment are often insufficient to resolve 
these problems.
95 
Pro-calcitonin is currently the most widely used,
96,97 
but the search 
is on for other biomarkers offering better sensitivity and specificity.
97,98 
In the future, 
genomics may provide a better answer to these problems,
98,99 
but at the moment 
further research is needed on gene expressions before this marker (or others) can be 
widely used in clinical practice.   
 
Another current focus of research is the identification of the causative microorganism 
in a timely fashion. 
96,100,101 
Matrix-Assisted Laser Desorption Ionization Time-of-
Flight Mass Spectrometry or MALDI-TOF MS (sometimes without the MS) is a 
particularly promising technique. It can identify either Gram-positive or Gram-
negative bacteria (to species level) within a matter of minutes, and only a relatively 
low bacterial load is needed for identification. A large recent observational study 
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demonstrated the clinical benefit of this rapid turn-around time.
101 
Indeed, a system of 
this kind, able to identify the pathogen and its sensitivity quickly and accurately in a 
point-of-care test, would signal a new era for the management of respiratory 
infections.    
In contrast with community-acquired respiratory infections, where there are different 
scores to stratify by severity-of-illness. It is not a common practice to stratify the 
severity of an episode of respiratory infection in MV patients. However, it is obvious 
that VARIs are heterogeneous and they need to be compared. Lisboa and colleagues 
designed the VAP PIRO score to stratify risk of death. It combines information on 
Predisposition (comorbidities),  Injury (bacteremia), Response (systolic blood 
pressure under 90 mmHg or use of vasopressors) and Organ failure (ARDS) This is a 
single score that classifies patients in three categories (0-1, 2 and 3-4) depending the 
risk of ICU mortality: low (1 of 8), intermediate (1 of 2) and high (4 of 5).
102 
A cohort 
validation, demonstrated a good correlation with health care resources use.
102 
Further 
research should be conducted to refine the tool, and perhaps to add biomarkers in the 
intermediate severity in order to improve its stratification capacity.  
Regarding the possibility to avoid VARI with antibiotic prophylaxis, in a prospective 
randomised study of major heart surgery patients, Bouza et al. assigned patients to 
either “standard of care” or to three days of prophylactic antibiotics (meropenem and 
linezolid).
103 
No patient-centred outcome benefits (i.e. mortality, ventilatory days, 
ICU length of stay) were found, but the authors observed a significantly lower 
incidence of VARI (combined VAP and VAT) in the intervention group and a 4.5-day 
delay in the onset of pneumonia.
103 
They also found an association between three days 
of pre-emptive treatment and an increase in resistance to linezolid.
103 
In a previous 
study our group established that an antimicrobial regimen of more than two days may 
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be associated with increased resistance,
104 
 and may modify the gut flora. Our group’s 
recent finding that VAP can be prevented with a single dose, as is the case in surgical 
prophylaxis, underlines the importance of appropriate stewardship in the ICU.
105 
  
 
Lastly, inhalation is likely to establish itself as a new means of antibiotic delivery. 
Rationale for using inhaled therapy include ability to achieve high lung tissue 
concentrations minimizing systemic absorption 
106, 107
 . In humans, Lu et al. 
108
  
described a study using nebulized ceftazidime (15 mg·kg(-1)·3 h(-1)) and amikacin 
(25 mg·kg(-1)·d(-1)) and showed that nebulization of antibiotics provided high lung 
tissue concentrations and rapid bacterial killing in ventilator-associated pneumonia 
caused by Pseudomonas aeruginosa. A recent study indicated comparable outcomes in 
patients with multidrug-resistant non-fermentative GNB when high dose colistin 
(5MU/8h) was nebulized, either in isolation or combined with parenteral treatment.
 109
 
This method for administering high concentrations of antibiotics in the distal airways 
enhances bacterial killing in the case of organisms with very high MICs and 
customized use according to the pathogen and the MIC is an opportunity for further 
research. Potential adverse events, such as blocking of the expiratory limb of the 
ventilator or bronchospasm and contraindications in severe hypoxemia are potential 
limitations that require further research. 
 
Conclusions 
Respiratory infections in mechanically ventilated patients present in the form of 
severe sepsis or septic shock in intubated patients. Purulent respiratory secretions are 
required for diagnosis, but differentiating between pneumonia and tracheobronchitis 
based only on clinical findings is a clinical challenge. Both presentations are 
 42 
associated with prolonged MV period and ICU stay, providing rationale for therapy. 
Key VARI management issues are: what is the pathogen, initial antibiotic choice and 
decisions depending on resolution pattern and criteria. New opportunities for research 
include role for biomarkers, earlier etiological diagnosis with molecular diagnosis 
techniques and optimization and customization of therapy.  
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Table 1. Top three pathogens of VAP reported in six studies published during the past 
decade.
20,22-26
 
Koulenti et al. EUVAP/CAP 
study group, 2009  
Prospective multicenter study;        
27 ICUs of 9 European 
countries; 465 cases of VAP
*
 
Overall 
 
S.aureus                32.6%            
-------------(MRSA 18.0%)                                    
-------------(MRSA 14.6%) 
P.aeruginosa       22.8% 
A.baumannii        20.2% 
Early-onset (< 5 
days) 
MSSA            27.6% 
P.aeruginosa  17.9% 
MRSA             12.4% 
Late-onset (>5 days) 
A.baumannii    26.5% 
P.aeruginosa   26.1% 
MRSA             16.1 % 
Esperatti et al., 2010 
Prospective single center 
Spanish study; 164 VAP cases 
** 
P.aeruginosa             24.0% 
MSSA                      14.0% 
MRSA                      9.0% 
Kollef et al., 2005 
Retrospective multicenter 
study, 59 US hospitals, 499 
culture-positive VAP cases 
MSSA                       28.5% 
P,aeruginosa            21.2% 
MRSA                      19.0% 
Lee MS et al., 2013 
Prospective multicenter study; 
31 US community hospitals; 
247 VAP cases
**
 
MRSA                       24.5% 
Pseudomonas spp      14.0% 
Klebsiella spp            11.9% 
Canadian Critical Care 
Trials, 2006 Group, 2006 
Prospective, multicenter study; 
28 ICUs in Canada & USA; 
739 VAP cases** 
 S.aureus                    17.2% 
H.influenzae              13.4%      
Enterobacter spp        9.3% 
Bekaert M et al.; 
OUTCOMEREA Study 
Group, 2011
***
 
Longitudinal prospective 
French multicenter 
Outcocomerea database; 685 
patients with microbiologically 
confirmed VAP*** 
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Figure 1. Depiction of the main proposed pathogenetic correlations between VAT 
and VAP. 
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Figure 2. Median (25-75 percentiles) onset of VAP by pathogen (onset as days after 
intubation). Data of 465 episodes of VAP from the EU-VAP/CAP Study database 
(only the first episodes of pneumonia were included in the analysis). 
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Figure 3. Approach to the work-up of Ventilator-Associated Respiratory Infections 
(VARI). 
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INTRODUCTION 
 
Ventilator-associated pneumonia (VAP), a clinical situation associated with 
high morbidity and mortality, is the most prevalent infectious complication in 
intensive care unit (ICU) patients (1 - 3). Microbiological data, obtained using an 
invasive or non-invasive strategy are essential to the evaluation of the appropriateness 
of antibiotic therapy, an important determinant of outcome in these patients (4-6). 
Moreover, the monitoring of biomarkers may play a role in prognosis assessment (7-
9), although its use and its relation to the inflammatory response have been discussed. 
Many studies (9-11) have focused on the search for prognostic markers in 
septic patients, particularly in those with VAP, and have proposed strategies for 
individualizing and optimizing treatment. Several recent studies assessed biomarkers 
as useful tools to evaluate VAP patients evolution, either using procalcitonin or C-
reactive protein (CRP (11, 12). The use of CRP as a marker of evolution and/or 
appropriateness of antibiotic treatment may be a promising strategy to anticipate the 
evaluation of antibiotic effectiveness. However, some specific populations has never 
been studied. 
 Many critically ill patients survive their initial acute illness but go on to 
experience persistent organ failures necessitating prolonged intensive care, a 
syndrome known as chronic critical illness (CCI) (13). CCI is characterized by high 
hospitalization costs, frequent post-acute care use, and poor long-term survival (14). 
CCI patients are particularly susceptible to infections, for many reasons.  It includes 
an immunologically deficient state commonly referred to as “immune exhaustion,” in 
which diminished physiological reserves impair the patient’s ability to fight infections 
or risk for acquiring virulent nosocomial organisms because they are cared for in an 
environment where multidrug-resistant organisms thrive (15,16). No data on clinical 
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or particular characteristics of VAP or biomarkers evolution in this specific subset of 
patients is available. 
We designed this study to evaluate: 1) the patients characteristics and 
outcomes in chronic critically ill patients developing VAP; 2) the evolution of 
biomarkers according to the presence of CCI using serum C-reactive protein as a 
biochemical marker of inflammatory response.  
We hypothesized that CRP peak values and its kinetics would be altered in 
patients with chronic critically illness developing VAP. 
 
MATERIALS AND METHODS  
Study Setting and Population 
A secondary analysis of a prospective observational study including patients 
with suspected ventilator-associated pneumonia (VAP) in the ICU for surveillance 
purpose. The cohort included mechanically ventilated patients from Hospital de 
Clinicas de Porto Alegre (Brazil), a large urban hospital affiliated to teaching 
institution, during 2008-2013. The data collection was approved by institutional ethics 
committee. 
Baseline Assessment, Definitions and Data Collection 
Suspicion of VAP required the radiographic appearance of a new, persistent 
pulmonary infiltrate in conjunction with purulent respiratory secretions, and at least 
one of the following criteria: temperature>38oC or <35,5oC, white blood cell count 
>10.000/mm3 or < 4000/ mm3(1). 
Microbiological data on all these episodes were obtained from quantitative 
tracheal aspirate performed on the day of pneumonia onset (baseline). Tracheal 
aspirates were required to have more than 25 neutrophils present on Gram stain, with 
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ten epithelial cells or fewer per high-power field to be accepted for culture of 
potential pathogens. Microorganisms were identified by standardized laboratory 
methods. Tracheal aspirate cultures and other study variables were collected within 8h 
of clinical suspicion in all patients with criteria of suspected VAP. Empirical 
antimicrobial therapy was considered appropriate when all isolates were susceptible 
in vitro to at least one antibiotic in use and institution has an empirical therapy 
protocol based on local microbiologic data and specific patient risk factors as 
previous exposure to antibiotics, previous pathology and time to onset of VAP. 
All laboratory and physical examination data allowing the determination of 
APACHE II score were recorded prospectively in a computerized database 24h after 
ICU admission as well as all comorbidities. The following data were collected at ICU 
admission: age, gender, baseline diagnostic, admission type, presence of 
comorbidities (cardiovascular, diabetes, Chronic obstructive pulmonary disease, renal 
dysfunction, cirrhosis, cancer, dementia, presence of AIDS), ICU and hospital length 
of stay. Mortality rate was evaluated at ICU and hospital discharge. Chronic critical 
illness was evaluated in those patients with more than 14 days (14) on mechanical 
ventilation. 
CRP levels were measured in serum using an automated nephelometric 
technique. CRP basal level was defined as that measured at day of VAP diagnosis. 
CRP variation was evaluated through a CRPratio defined as the ratio between CRP 
levels on follow-up (72-96h) and CRP levels on baseline. CRPmax was the higher 
CRP value identified within first 72h of diagnosis, based on this biomarker kinetics. 
Also, the ratio between CRPmax/CRPbasal was measured as an index of the 
maximum amplitude of CRP variation within 72h. 
Statistical Analysis 
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Descriptive statistical analysis was performed. Continuous data were 
compared using the unpaired Student’s t-test or Mann-Whitney test when appropriate. 
Proportions were compared using the Chi-square and Fisher’s test when necessary. 
The correlation was checked with Spearman’s correlation test. The variation of values 
from baseline was compared using paired t-test. Survival analysis was performed 
using Cox proportional hazard analysis. Analysis of covariance (ANCOVA) has been 
performed for paired values on baseline and follow-up. All p values were two-tailed 
and a p<0.05 was considered significant. Statistics were computed with the STATA 
for Mac 14.0 statistical package. 
 
RESULTS 
We included 405 patients with VAP diagnosis. Most were male (61.1%). 
Mean APACHE II score was 19.9±10,5 and median age was 60 (IQR 45;71) years. 
Median LOS in ICU was 22 (IQR 15;36) days and length of mechanical ventilation 
median was 9 (IQR 6-13) days. Overall mortality rate was 55.7%. Mean days of 
mechanical ventilation before VAP diagnosis were 11.6±11.2 days. The baseline 
characteristics of survivors and non-survivors are described in Table 1. Etiology of 
VAP episodes is described in Table 2, showing an increased prevalence of 
Acinetobacter species and Pseudomonas aeruginosa in CCI patients. Multidrug-
resistant pathogens were isolated in 171 patients (42.2%). Overall, appropriateness of 
empirical therapy was 81.4%, with a higher rate of appropriateness in CCI patients 
when compared to non-CCI patients (Table 3). 
We found 99 patients (24.4%) with more than 14 days of mechanical 
ventilation, defined as CCI. When compared episodes in patients with and without 
chronic critical illness, presence of chronic renal disease, dementia, presence of > 2 
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comorbidities  and previous use of antibiotic were identified as risk factors associated 
with CCI (Table 3). Also, CCI patients present more frequently MDR pathogens than 
no-CCI patients (63.6% vs 35.3%, OR 3.21 95%CI 2.00-5.14). 
Outcomes of CCI patients VAP episodes were not significantly different 
compared to no CCI patients, with similar crude ICU-mortality (58.6% vs 54.6%, OR 
1.18 95%CI 0.74-1.86). However, after Cox regression analysis with adjustment for 
severity of illness at admission and MDR pathogen etiology of VAP episode, we 
found a significant increase on the hazard risk in CCI patients (HR 2.35 95% CI 1.71-
3.22).  
CRP evolution 
CRP levels and kinetics were not significant different when comparing 
survivors and non-survivors without adjustment for antimicrobial appropriateness 
(Table 1). However, CRP ratio estimated marginal means were different when 
comparing survivors and non-survivors, after adjustment for covariance – ANCOVA 
– with basal levels (0.82 95% CI 0.68-0.95 vs 1.02 95% CI 0.90-1.13, p<0.05). When 
assessing CRP as a surrogate of inflammatory response in CCI patients, we found no 
difference in the response pattern, compared to patients without CCI. 
 Basal serum CRP levels were not different when comparing CCI and no CCI 
patients (167.3±77.0 vs 168.7±87.6, p=0.94) at time of diagnosis. Also, CRPmax 
reached within 72h of diagnosis (175.0±79.2 vs 182.9±87.2, p=0.58) or relative 
increase in CRP levels (CRPratio and CRPmax/CRPbasal) (0.86±0.49 vs 0.93±0.70, 
p=0.46; 1.09±0.37 vs 1.20±0.56, p=0.21) were not significant different between 
patients presenting CCI and those without CCI  (Figure 1). Even when analyzing 
only patients with appropriate empirical antimicrobial therapy, no difference was 
found in comparison between CCI and non-CCI patients (Table 4). 
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In addition, the analysis of covariance showed no significant differences on 
follow-up levels of serum CRP after adjustment for baseline values (Table 4). 
DISCUSSION 
 This is an original study assessing characteristics of VAP episodes in CCI 
patients. CCI population is increasing in ICUs. Although advances in critical care 
have enabled more patients to survive an acute critical illness, they also have created a 
large and growing population of chronically critically ill patients with prolonged 
dependence on mechanical ventilation and other intensive care therapies. This high 
dependent population, needing prolonged respiratory support is at higher risk for 
developing nosocomial infections, particularly ventilator-associated pneumonia. Our 
findings suggest some characteristics such as age, severity of illness at ICU 
admission, some comorbidities are associated with worse outcomes in this subgroup 
of patients. However, interestingly, inflammatory response to infectious damage 
assessed using CRP as a surrogate, were not different when comparing VAP episodes 
in CCI and no-CCI patients. Nor basal serum CRP or peak levels obtained within 72h, 
or the ratio of increase in CRP levels were different comparing both groups. 
The burden of chronic critical illness is respiratory failure, its increasing 
prevalence and epidemiological aspects described in the last years is in close relation 
with the increasing requirement of prolonged dependence on mechanical ventilation 
in ICUs around the globe. Long-term mortality is high, approaching rates of 40% to 
60% at one-year in inclusive cohorts (17). Patients have a very high symptom burden 
during the weeks of prolonged ventilation and chances of living at home with 
functional independence at the end of the year are as low as 10% (18). Although the 
term ‘‘prolonged mechanical ventilation’’ has been used in the literature to describe 
periods of ventilator dependence ranging from 2 days to 4 weeks (19,20), a clear 
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definition of CCI is still missing in the literature, and several studies purposed 
different definitions (21,22). A period of mechanical ventilation, ranging from 2 to 30 
days, has been used to define the majority of cohorts for longitudinal studies (19-21). 
In our study, we identified patients with more than 14 days of mechanical ventilation 
to define CCI, according to Hough et al. et al (14).  
Besides prolonged ventilator dependence, evidence suggests that chronic 
critical illness is a syndrome comprising additional characteristics including high 
susceptibility to complications, brain dysfunction manifesting as coma or delirium; 
skin breakdown associated with nutritional deficiencies, edema, incontinence, and 
prolonged immobility (15,21). All together, these characteristics also are associated 
with a higher vulnerability to develop nosocomial infections, frequently by multidrug 
resistant (MDR) microorganisms. 
As expected, our cohort show that patients with prolonged mechanical 
ventilation present a microbiological profile in which multidrug resistant pathogens 
are more predominant when comparing CCI patients with VAP with episodes in 
patients without CCI, more specifically non-fermenting Gram-negative bacilli – 
Acinetobacter and Pseudomonas species. A higher prevalence of MDR pathogens is 
expected in this population, as colonization of critically ill patients by these pathogens 
is a progressive phenomena developing during the stay of patient in ICU (23). Also, 
as already described in the literature, outcomes in patients developing CCI are 
significantly worse, compromising ICU survival in VAP episodes in patients with 
CCI. This finding was not surprisingly in our study, but difference was present only 
after adjustment for severity of illness and MDR pathogens. This might be due to 
some aspects: First, patients developing VAP within the first 2 weeks of mechanical 
ventilation might be at higher risk for worse outcomes as VAP is considered a 
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preventable phenomena and its occurrence might be associated with higher severity at 
admission or failures on process of care – we adjust for one of these variables as 
process of care variables were not available for this analysis; second, VAP episodes 
early on evolution are associated with more virulent pathogens, and attributable 
mortality in early episodes might be more relevant; third, patients with CCI have 
more episodes due to MDR pathogens, and some of these low virulence pathogens 
such as Stenotrophomonas might be only an epiphenomena, without increment on 
CCI patients  risk for worse outcome. So, effect of CCI only appears after adjustment 
for some of these conditions. Although attributable mortality in VAP is a 
controversial issue, it does prolong mechanical ventilation and length of stay in the 
ICU (24), causing a positive feedback with risk and outcomes associated with CCI.  
A unique aspect of our study is to assess whether developing CCI would affect 
response from an infectious insult, such as a VAP episode. Several studies has used 
biomarkers such as CRP and procalcitonin as surrogates for host response in severe 
infections (10-12). CRP is one of the most important acute-phase reactant in humans 
and the most used and studied biomarker of inflammation due to the wide availability, 
diagnostic accuracy, and relatively low costs of laboratory assays. Its main biological 
functions include activation of the classical complement pathway and binding of 
bacteria with subsequent activation of leukocyte-mediated cytotoxicity (25). 
Strategies based on biomarkers such as CRP in evolution assessment after treatment 
might be useful to evaluate appropriateness of empirical therapy and even 
antimicrobial duration. We found a significant difference when comparing CRP levels 
between survivors and non-survivors, as already shown in other studies (11). Values 
of serum CRP for evolution and prognosis assessment of patients with severe 
infections, and VAP specifically, have been evaluated in several studies (10-12). A 
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decrease in serum CRP level on the fourth day of evolution was predictive of survival 
and appropriateness of antimicrobial therapy (12) in VAP patients. Povoa et al. (10) 
identified patterns of serum CRP response and its relationship with prognosis in VAP 
and suggested that serum CRP response may be useful in recognition the host 
response and anticipation of individual clinical course. No data, however, is available 
in CCI patients.  
Cabrera-Cancio M (15) describes alterations not completely understood in 
immune response occurring during CCI. Following the acute or initial hyper- 
inflammatory response to sepsis, an immune system down-regulation can lead to 
prolonged immune dysfunction. This period of “immune paralysis” has consequences: 
it limits the ability to fight infections and predisposes the patient to nosocomial 
infections and multi-organ dysfunction. Patients who survive this initial systemic 
inflammatory response syndrome enter a state of immune suppression and 
dysfunction (16). Additionally, these patients frequently have comorbidities that 
precede the acute event. Their defenses might be already impaired at the beginning of 
the ICU admission by preexisting illnesses (15). Considering these potential 
confounders, we assessed CRP behavior in this subgroup of patients. Our data show 
no difference in basal CRP levels at time of diagnosis, nor at CRP peak value 
obtained within 72h of diagnosis, nor the CRP ratio in 96h in comparison with basal 
CRP serum levels, when comparing VAP episodes in patients with CCI and patients 
without CCI, suggesting that, at least regarding CRP role in the host response, CCI 
patients has the same response than non CCI patients. These findings are more robust 
as confirmed by analysis of covariance, adjusting for potential baseline imbalance. 
This absence of difference persisted, even when considering only patients with 
appropriate empirical antibiotic therapy. 
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Our study has several limitations. It is an observational study and no causal 
inference can be determined. We did not collect any new severity assessment score 
such as SAPS3, only APACHE II. It is possible that undiscovered variables might 
explain the apparent absence of effect of CCI on CRP behavior in VAP patients. In 
addition, we could only assess response in VAP patients using CRP levels. Perhaps, 
other biomarkers such as procalcitonin, interleukins, cytokines or other PAMPs and 
DUMPs could identify more specific qualitative or quantitative alterations in host 
response in this population. But as CRP is part of innate immune response and it is a 
mechanism well preserved in evolutionary chain, the suggestion that it is preserved 
might be useful to define characteristics or subgroups of patients developing CCI at 
higher risk to develop VAP or with worse associated outcomes. Also, our study could 
not assess or speculate on basic mechanisms responsible for the persistence of CRP 
response in CCI patients. Still, several CCI definitions are available in the literature, 
but we select 14 days as the most sensitive criteria available. 
CONCLUSION 
In conclusion, in this cohort of patients with VAP, we described that those 
patients developing CCI present VAP with worse prognosis, with higher hazard risk 
for ICU negative outcome after adjustment for severity of illness at admission, MDR 
pathogens and more comorbidities. However, such findings does not appear related to 
a compromised response to infectious episodes as assessed by CRP serum levels at 
moment of diagnosis, nor its evolution within the first 72-96h. Our data suggest that 
using CRP as a surrogate for clinical evolution in patients with CCI might be still 
appropriate as we were not able to find changes in response pattern comparing 
patients with or without CCI. Further studies should prospectively assess CRP and 
other biomarkers role in management strategies in CCI patients. 
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Table 1. Clinical characteristics of VAP patients comparing survivors and non-
survivors 
 
 
  Survivors Non-survivors p 
Number of patients                                          180        226   
Age (mean (SD))         54.4 (17.3) 59.8 (17.4) <0.001 
Gender (male/female) (%) 63,3/36,7% 59,3/40,7 0,42 
APACHE II (mean (SD)) 20.7 (7.6) 23.7 (7.6) <0.001 
LOS MV before PAV (median [IQR]) 8 (4-12) 9 (6-14) 0.03 
Admission type (%)   0.76 
Medical                                                                                                                                                     108 (60.0%) 139 (61.5%)  
Surgery 72 (40.0%) 87 (38.5%)  
Heart failure class IV (n (%)) 12 (6.7%) 26 (11.5%) 0.13 
AIDS (n (%)) 11 (6.1%) 18 (8.0%) 0.60 
Cirrhosis (n (%)) 12 (6.7%) 18 (8.0%) 0.76 
CRD (n (%)) 9 (5.0%) 18 (8.0%) 0.32 
Diabetes (n (%)) 22 (12.2%) 38 (16.8%) 0.25 
Hypertension (n (%)) 50 (27.8%) 63 (27.9%) 0.99 
Dementia (n (%)) 4 (2.2%) 13 (5.8%) 0.12 
Cancer (%) 26 (14.4%) 60 (26.5%) <0.001 
COPD (%) 11 (6.1%) 22 (9.7%) 0.25 
More than 2 Comorbidities (n (%))* 85 (47.2%) 140 (61.9%) <0.001 
CCI (n (%)) 41 (22.8%) 58 (25.8%) 0.56 
ICU LOS, days, median [IQR] 22 (11-38) 22(11-34) 0.98 
MV duration, days, median [IQR] 16 (11-29) 20(13-31) 0.04 
Appropriateness of ATB therapy (%) 147 (81.7%) 184(81.4%) 0.99 
Previous ATB (%) 72 (40.0%) 103 (45.6%) 0.27 
MDR pathogen (%) 69 (38.3%) 103 (45.6%) 0.16 
Basal serum CRP (median (IQR)) 163 (108-196) 168 (126-213) 0.77 
CRP maximum within 72h (median (IQR)) 168 (119-201) 179 (135-243) 0.30 
CRP at 96h (median (IQR)) 116 (81-165) 128 (83-178) 0.29 
 
 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range; LOS – length of stay; MV – mechanical ventilation; CRD – Chronic renal disease; COPD – 
chronic obstructive pulmonary disease; ATB – antibiotic therapy; CCI – chronic critical illness; MDR 
– multidrug resistant. 
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Table 2 – Etiology of VAP episodes in CCI and non-CCI patients 
 
 
 ETIOLOGY CCI Non-CCI p 
Enterobacteriaceae 33 (33.3%) 91 (29.7%) 0.58 
                E. coli 3 (3.0%) 10 (3.3%)  
                Enterobacter spp. 10 (10.1%) 29 (9.5%)  
                 Klebsiella spp. 14 (14.1%) 43 (14.1%)  
                Other Enterobacteriaceae 6 (6.1%) 9 (2.9%)  
S. aureus 16 (16.2%) 59 (19.3%) 0.59 
                  MSSA 10 (10.1%) 48 (15.7%)  
                  MRSA 6 (6.1%) 11 (3.6%)  
Pseudomonas aeruginosa 29 (29.3%) 40 (13.1%) <0.001 
Acinetobacter sp. 28 (28.3%) 60 (19.6%) 0.06 
Streptococcus pneumoniae 0 5 (1.6%) 0.49 
Haemophilus influenzae 1 (1.0%) 12 (3.9%) 0.26 
Serratia sp. 4 (4.0%) 12 (3.9%) 0.99 
Stenotrophomonas maltophila 8 (8.1%) 17 (5.6%) 0.40 
Polymicrobial episodes 25 (25.3%) 82 (26.8%) 0.87 
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Table 3. Comparison of clinical characteristics and outcomes according to presence 
of chronic critical illness (CCI) in ICU patients 
 
  CCI No-CCI p 
Number of patients                                  99 306  
Age (mean (SD))         57.1 (18.4) 58.2 (17.5) 0.72 
Gender (male/female) (%) 65,7/34,3% 59,5/40,5% 0.29 
APACHE II (mean (SD)) 21.4 (10.9) 21.1 (9.7) 0.86 
LOS MV before PAV (median [IQR]) 19 (17-27) 7 (4-10) <0.001 
Admission type (%)   0.41 
Medical                                                                                                                                                     64 (64.6%) 183 (59.8%)  
Surgery 35 (35.3%) 123 (40.2%)  
Heart failure class IV (n (%)) 9 (9.1%) 29 (9.5%) 0.99 
AIDS (n (%)) 9 (9.1%) 20 (6.5%) 0.51 
Cirrhosis (n (%)) 4 (4.0%) 26 (8.5%) 0.20 
CRD (n (%)) 11 (11.1%) 16 (5.2%) 0.04 
Diabetes (n (%)) 19 (19.2%) 41 (13.4%) 0.21 
Hypertension (n (%)) 27 (27.3%) 86 (28.1%) 0.98 
Dementia (n (%)) 8 (8.1%) 9 (2.9%) 0.04 
Cancer (%) 26 (26.3%) 60 (19.6%) 0.21 
COPD (%) 8 (8.1%) 25 (8.2%) 0.99 
More than 2 Comorbidities (n (%))* 76 (76.7%) 149 (48.7%) <0.001 
ICU LOS, days, median [IQR] 40 (26-52) 19 (14-28) <0.001 
Appropriateness of ATB therapy (%) 90 (90.9%) 240 (78.4%) <0.05 
Previous ATB (%) 66 (66.7%) 108 (35.3%) <0.001 
MDR pathogen (%) 63 (63.6%) 108 (35.3%) <0.001 
Basal serum CRP (median (IQR)) 154 (124-193) 167 (108-206) 0.88 
CRP maximum within 72h (median (IQR)) 161 (129-195) 175 (132-216) 0.45 
CRP at 96h (median (IQR)) 124 (87-168) 125 (79-171) 0.83 
ICU Mortality (n(%)) 58 (58.6%) 167 (54.6%) 0.56 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range; LOS – length of stay; MV – mechanical ventilation; CRD – Chronic renal disease; COPD – 
chronic obstructive pulmonary disease; ATB – antibiotic therapy; CCI – chronic critical illness; MDR 
– multidrug resistant. 
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Table 4. Comparison of CRP response according to presence of chronic critical 
illness (CCI) in ICU patients 
 
  CCI Non-CCI p 
CRUDE       
Basal serum CRP (mean (SD)) 167.6 (77.0) 168.7 (87.6) 0.94 
CRP maximum within 72h (mean (SD)) 175.0 (79.2) 183.0 (87.2) 0.58 
CRP at 96h (mean (SD)) 135.5 (79.2) 130.7 (75.4) 0.71 
CRP ratio (median [IQR]) 0.96 (0.72-1.36) 1.08 (0.80-1.49) 0.30 
ONLY APPROPRIATE ANTIBIOTIC 
THERAPY 
   
Basal serum CRP (mean (SD)) 167.4 (74.0) 171.0 (88.0) 0.81 
CRP maximum within 72h (mean (SD)) 172.4 (78.5) 186.0 (87.4) 0.36 
CRP at 96h (mean (SD)) 134.5 (81.2) 133.9 (76.0) 0.96 
CRP ratio (median [IQR]) 0.84 (0.58-1.00) 0.76 (0.56-1.05) 0.93 
ANALYSIS OF COVARIANCE – ESTIMATED 
MARGINS ADJUSTED BY BASAL CRP 
LEVELS 
   
CRP maximum within 72h (mean (95% CI)) 175.7 (164.9-
186.5) 
182.7 (176.3-
189.1) 
0.27 
CRP at 96h (mean (SD)) 135.9(117.6-154.1) 130.6(119.8-
141.4) 
0.63 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range 
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Figure 1. CRP evolution in CCI and non-CCI patients with VAP 
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INTRODUCTION  
VAP is the most common nosocomial infection in ICU and represents 25% of 
all ICU infections, with high cost and impact on outcomes (1-3). Although the 
attributable mortality VAP is a controversial issue, it does prolong mechanical 
ventilation and length of stay in the ICU (3-5). Moreover, the monitoring of 
biomarkers may play a role in prognosis assessment (6), although its use and its 
relation to the inflammatory response have been discussed. Many studies (7 -10) have 
focused on the search for prognostic markers in septic patients, particularly in those 
with VAP, and have proposed strategies for individualizing and optimizing treatment. 
Several recent studies assessed biomarkers as useful tools to evaluate VAP patients 
evolution, either using procalcitonin or C-reactive protein (CRP (7-10). In addition, 
biomarkers usefulness is some specific subsets of patients have been discussed. 
The impact of age on the outcome of critically ill patients remains 
controversial (11). Older patients now receive a substantial share of health care 
resources, including those related to intensive care (12). In addition, the physiology of 
inflammatory response is modified by the aging process and is substantially affected 
by multimorbidity and disability (13). So, the clinical significance of serum CRP 
determination has not been completely clarified in older subjects with acute infection, 
especially in the light of the age-related rearrangements in immunity and cytokine 
production (14). Few data is available regarding CRP kinetics in older patients with 
infection (15-19). As such, even if many data are present about the CRP and VAP 
patients, the current knowledge does not allow recommending serial CRP 
measurements to guide therapeutic choices in older VAP patients. 
We designed this study to evaluate: 1) the impact of age on outcomes in 
critically ill patients developing VAP; 2) the evolution of biomarkers according to age 
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in these patients using serum C-reactive protein levels and kinetics as a biochemical 
marker of inflammatory response.  
We hypothesized that CRP peak values and its kinetics would be altered in 
older patients with critically illness developing VAP. 
 
MATERIALS AND METHODS  
 
Study Setting and Population 
A secondary analysis of prospective observational study including patients 
with suspected ventilator-associated pneumonia (VAP) in the ICU for surveillance 
purpose. From 2008 to 2013 all patients with suspected VAP were included. The 
cohort included mechanically ventilated patients from Hospital de Clinicas de Porto 
Alegre (Brazil), a large urban hospital affiliated to teaching institution. The data 
collection was approved by institutional ethics committee. 
 
Baseline Assessment, Definitions and Data Collection 
Suspicion of VAP required the radiographic appearance of a new, persistent 
pulmonary infiltrate in conjunction with purulent respiratory secretions, and at least 
one of the following criteria: temperature>38oC or <35,5oC, white blood cell count 
>10.000/mm3 or < 4000/ mm3 (1). 
Microbiological data on all these episodes were obtained from quantitative 
tracheal aspirate, performed on the day of pneumonia onset (baseline). 
Microorganisms were identified by standardized laboratory methods. Tracheal 
aspirate cultures and other study variables were collected within 8h of clinical 
suspicion in all patients with criteria of suspected VAP. 
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Empirical antimicrobial therapy was considered appropriate when all isolates 
were susceptible in vitro to at least one antibiotic in use and institution has an 
empirical therapy protocol based on local microbiologic data and specific patient risk 
factors as previous exposure to antibiotics, previous pathology and time to onset of 
VAP. 
All laboratory and physical examination data allowing the determination of 
APACHE II score were recorded prospectively in a computerized database 24h after 
ICU admission as well as all comorbidities. Pre-existing Chronic obstructive 
pulmonar disease was defined as a disease state characterized by the presence of 
airflow limitation due to chronic bronchitis or emphysema (15). AIDS, dementia and 
cancer presence were clinically defined. Chronic Heart Failure was considered in 
patients admitted with New York Heart association (NYHA) class III and IV. 
Chronic Hepatopathy was considered in patients with documented biopsy proven 
cirrhosis, documented portal hypertension, episodes of past upper gastrointestinal 
bleeding attributed to portal hypertension or previous episodes of hepatic 
encephalopathy. Chronic Renal Failure was considered in patients receiving chronic 
hemodialysis.    
CRP levels were measured in serum using an automated nephelometric 
technique.  CRP basal level was defined as that measured at day of VAP diagnosis. 
CRP variation was evaluated through a CRPratio defined as the ratio between CRP 
levels on follow-up (72-96h) and CRP levels on baseline. CRPmax was the higher 
CRP value identified within first 72h of diagnosis, based on this biomarker kinetics. 
Also, the ratio between CRPmax/CRPbasal was measured as an index of the 
maximum amplitude of CRP variation within 72h. 
Statistical Analysis 
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Descriptive statistical analysis was performed. Continuous data were 
compared using the unpaired Student’s t-test or Mann-Whitney test when appropriate. 
Proportions were compared using the Chi-square and Fisher’s test when necessary. 
Logistic regression was also performed to identify factors associated with ICU 
mortality after univariate evaluation and Hosmer-Lemeshow goodness-of-fit statistics 
was used to evaluate its calibration. The correlation was checked with Spearman’s 
correlation test. The variation of values from baseline was compared using paired t-
test. Analysis of covariance (ANCOVA) has been performed for paired values on 
baseline and follow-up. Impact of age in survival was tested using Cox proportional 
hazards analysis. Null model Martingale residuals were used to assess the functional 
form of age impact (12), and showed an upward bend around the age of 65 yrs. A 
model including a smoothing function of age was tested, but the nonlinearity was not 
significant, indicating that a linear fit was acceptable. To assess outcome predictors in 
young and elderly patients, the dataset was divided in two groups (<65 and >65 yrs), 
based on the functional form of age (Fig. 1). All p values were two-tailed and a 
p<0.05 was considered significant. Statistics were computed with the STATA for 
Mac 14.0 statistical package and SPSS 20.0. 
 
RESULTS  
In the study period, 405 patients fulfilled the eligibility criteria. The median 
age was 60.5 (IQR, 45.0; 71.0) years. The main patients’ characteristics are depicted 
in Table 1. Distribution of admission diagnosis category included: 247 (61.0%) 
medical, 155 (38.3%) surgical; and 6 (1.7%) trauma patients. Overall mortality rate 
was 55.7%. Overall, appropriateness of empirical antibiotic therapy was 81.4%. 
Etiology of VAP episodes is described in Table 2, suggesting a higher prevalence of 
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Enterobacteriaceae in older patients. 
Age was independently associated with survival time, adjusted by gender, 
severity of illness and comorbidities. In Figure 1, age was plotted against the 
martingale residuals showing that risk of death substantially influenced by age only 
after 65 yrs. From this point upward, there was an increase in the residual values. 
Based on the analysis of Figure 1, patients were stratified in two groups: younger 
(<65 yrs, 242, 59.6%) and elderly (>65 yrs, 164, 40.4%). Baseline characteristics 
comparison between younger and older patients is presented in the table 3. In 
univariate analysis, a higher ICU mortality was associated with older patients (OR 
1.94 95%CI 1.29-2.92). Also, in multivariable analysis, age >65 yrs was associated 
with higher ICU mortality (OR 1.72 95%CI 1.13-2.62) after adjustment for severity of 
illness at admission (Hosmer-Lomeshow goodness of fit p=0.62). 
CRP evolution and age 
Age, assesed as a continuous variable, has no significant correlation with basal 
serum CRP or CRPmax in VAP patients (Figure 2). Also, when assessing CRP as a 
surrogate of inflammatory response in patients according to age, we found no 
difference in the response pattern, comparing patients older than 65 with those with 
less than 65 years old (Figure 3).  
Basal serum CRP levels were not different when comparing older and younger 
patients (173.1±79.5 vs 164.9±88.6, p=0.51) at time of diagnosis. Also, CRPmax 
reached within 72h of diagnosis were not significant different between patients older 
than 65 and those younger than 65 years (177.2±76.6 vs 184.0±91.1, p=0.59). Even 
after considering only patients with appropriate empirical therapy, no difference was 
found (Table 4). 
In addition, the analysis of covariance showed no significant differences on 
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follow-up according to age group in the levels of serum CRP, after adjustment for 
baseline values (Table 4). 
 
DISCUSSION 
 Our analysis evaluated the impact of age on outcomes in critically ill patients 
developing VAP and the evolution of biomarkers according to age in these patients 
using serum CRP levels and kinetics as a biochemical marker of inflammatory 
response. We found no difference in CRP levels at baseline, maximum CRP level 
within 72h, ratio between CRP levels at 96h and baseline, or variation of CRP levels 
within 96h when comparing older and younger patients. We hypothesized that age 
would affect outcomes in VAP patients and identified impact of age on survival only 
after 65 years as suggested by Martingale residual analysis resulting from a null-
model of Cox survival hazard analysis. Although older patients had a higher rate of 
comorbidities, more severe burden of disease and worse outcomes, with higher 
mortality and prolonged length of stay, CRP levels and kinetics were not different. 
Our findings suggest that the same biomarker-variation based strategies used for VAP 
patients in ICU might keep its validity for an older VAP-patients population. 
 Several specific subgroups of patients with VAP have been evaluated in the 
literature. Trauma (20,21), patients with cancer (22), COPD patients (23) are some of 
the specific conditions evaluated in VAP. Our study is novel as we assessed and 
compare outcomes according to age in critically ill patients with VAP diagnosis and 
how it affects host-response, based on CRP evolution. We evaluated age as a 
continuous variable and could identify a specific cut-off in which age begins to affect 
outcome in VAP patients around 65 years. We used a statistical approach already 
published in critically ill cancer patients (12). We found some difference in 
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microbiology in older patients, but our sample was not large enough to determine a 
causal effect between age and risk for specific pathogens as many confounding 
factors such as comorbidities and severity of illness were more important in older 
patients subgroup. Regarding age and VAP, Blot et al. (24) assessed prevalence and 
associated outcomes in VAP patients according to age. In this study, an arbitrary cut-
off of age was used and 3 groups were defined (middle-aged (45-64ys), old (65-74ys) 
and very old patients (≥75ys)). Main findings in this study were no difference on VAP 
prevalence within three groups, an increasing of associated mortality along the three 
age-ranges, and a higher prevalence of Enterobacteriaceae in older patients, in 
accordance with our data. No difference was described on clinical symptoms except 
by a lower presence of new onset of fever in older patients. No data on biomarkers 
was assessed. Also, regional variations are expected for age effect on mortality and 
this study included only European patients. 
We decided to assess age impact on CRP behavior in VAP patients based on 
pathophysiological changes described in older patients with acute infection. The aging 
process has an important effect on immunity and inflammation, affecting host-
response, leading to chronic low-grade activation of inflammatory pathways and 
decreased response to novel antigens (immunosenescence) (13), affecting host-
pathogen interaction. Ticinesi et al. (14) describes that these differences include 
poorer T helper cell function, poorer B cell humoral response to neoantigens, reduced 
neutrophil, and macrophage cytotoxic function, and expansion of natural killer cells 
with apparent reduced functionality (25). Despite this, during acute infection, older 
subjects have a generally intact production of proinflammatory cytokines, including 
IL-1, TNF-α, and IFN-γ. Acute IL-6 production is even increased compared to adult 
subjects, and the duration of this response is generally longer (14,25). In fact, 
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immunosenescence mainly affects innate immunity in terms of reduced cell function 
(i.e. reduced adhesion, chemotaxis, and phagocytosis), but not in terms of systemic 
mediator release (26). It is suggested that these alterations on response might have a 
clinical impact on infection recognition, delay on treatment and inability to assess 
clinical response in older patients population (14). Despite many studies are available 
assessing CRP and acute infection in critically ill patients (14-19), and particularly, in 
respiratory infections (8-10), no study assessed specifically older patients with VAP 
and impact of age on CRP evolution. 
 In VAP patients, higher peak CRP values are generally associated with a 
higher intensity of inflammation, reflecting a more severe disease and thus a higher 
risk for adverse outcomes. The utility of serial biomarkers measurements during VAP 
treatment has been studied, suggesting that biomarkers may help guiding duration and 
quality of antibiotic therapy in sepsis. Values of serum CRP for evolution and 
prognosis assessment of patients with VAP have been evaluated in several studies (7-
10). A decrease in serum CRP level on the fourth day of evolution was predictive of 
survival  and appropriateness of antimicrobial therapy (9) in VAP patients. Povoa et 
al. (10) identified patterns of serum CRP response and its association with prognosis 
in VAP patients and suggested that serum CRP kinetics might be useful in the 
recognition the host response and anticipation of the individual clinical course. Few 
data are available regarding serum CRP levels, its kinetics and older patients.  
In older patients, CRP kinetics is not fully understood. Wester et al (27) 
evaluated patients hospitalized with acute bloodstream infections due to 
Streptococcus pneumoniae and Escherichia coli and observed a decline in CRP levels 
from the fourth day of stay onwards in both adult and geriatric patients, while CRP 
levels were generally comparable to baseline during the second and third day of stay. 
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However, the possible association of CRP kinetics with clinical outcomes was not 
verified in that study. Koppensteiner et al. evaluated surgical patients after hip or knee 
arthroplasthy and found that a decrease in CRP levels between day 2-4 after 
procedure predict a positive outcome in older patients (28).  
 Our findings suggest no correlation between age and any measure of serum 
CRP at baseline, peak of concentration within 72h or CRP levels at 96h. In addition, 
we found no difference on CRP kinetics and response pattern when comparing older 
and younger patients. It suggests CRP serial measurements remain a valid strategy to 
assess evolution of VAP in older patients, as our sample seems not to be affected by 
immunosenescence. 
Our study has several limitations. It is an observational study and no causal 
inference can be determined. Also, as a single-center study, specific aspects on 
admission restriction of older patients to the ICU could impact on results through 
selection bias. However, as we assessed a complication developed during ICU stay, 
this bias is minimized. Another potential selection bias derived from single-center 
design is that we did include a very small number of trauma patients. It is known that 
trauma patients, although younger than medical patients in epidemiological studies, 
are at higher risk for developing VAP (20). However, VAP associated outcomes in 
trauma patients are better when compared to medical patients (20). So, inclusion of a 
more substantial sample of this subset of patients could potentially change our results. 
Also, progressive increasing age of admitted patients in ICU, and as consequence, in 
the risk population and regional variability might have potentially affected the cut-off 
we found in our population. Still, we did not compare other cut-off age rather than 65 
years old. It is possible also that undiscovered confounding factors might explain the 
apparent absence of effect of age on CRP behavior in VAP patients. In addition, we 
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could only assess and compare host-response in older and younger VAP patients 
using CRP levels. Perhaps, other biomarkers such as procalcitonin, specific 
interleukins, cytokines or other PAMPs and DUMPs could identify more specific 
qualitative or quantitative alterations in host response in this population. Also, our 
study could not assess or speculate on basic mechanisms responsible for the 
persistence of CRP response in older patients.  
 
CONCLUSION 
In conclusion, our findings in this cohort of patients with VAP described that 
those older patients developing VAP had worse prognosis, with higher mortality, 
more severity of illness at admission and more comorbidities. We suggest this effect 
begins at 65 years old. Also, we found no difference on CRP serum levels at moment 
of diagnosis, nor its evolution within the first 72-96h when comparing older and 
younger patients using 65 years old as cut-off. No correlation was found between age 
and any CRP levels at baseline or kinetics. Our data suggest that using CRP as a 
surrogate for clinical response in older VAP patients might still be adequate as we 
were not able to find changes in response pattern comparing patients younger or older 
than 65 years. Further studies should prospectively assess CRP and other biomarkers 
role in management strategies in older critically ill patients. 
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Table 1. Comparison of baseline characteristics between survivors and non-survivors  
 
 
  Survivors Non-survivors p 
Number of patients                                        180       226   
Age (mean (SD))         54.4 (17.3) 59.8 (17.4) <0.001 
Gender (male/female) (%) 63,3/36,7% 59,3/40,7 0,42 
APACHE II (mean (SD)) 20.7 (7.6) 23.7 (7.6) <0.001 
LOS MV before PAV (median [IQR]) 8 (4-12) 9 (6-14) 0.03 
Admission type (%)   0.76 
Medical                                                                                                                                                     108 (60.0%) 139 (61.5%)  
Surgery 72 (40.0%) 87 (38.5%)  
Heart failure class IV (n (%)) 12 (6.7%) 26 (11.5%) 0.13 
AIDS (n (%)) 11 (6.1%) 18 (8.0%) 0.60 
Cirrhosis (n (%)) 12 (6.7%) 18 (8.0%) 0.76 
CRD (n (%)) 9 (5.0%) 18 (8.0%) 0.32 
Diabetes (n (%)) 22 (12.2%) 38 (16.8%) 0.25 
Hypertension (n (%)) 50 (27.8%) 63 (27.9%) 0.99 
Dementia (n (%)) 4 (2.2%) 13 (5.8%) 0.12 
Cancer (%) 26 (14.4%) 60 (26.5%) <0.001 
COPD (%) 11 (6.1%) 22 (9.7%) 0.25 
More than 2 Comorbidities (n (%))* 85 (47.2%) 140 (61.9%) <0.001 
CCI (n (%)) 41 (22.8%) 58 (25.8%) 0.56 
ICU LOS, days, median [IQR] 22 (11-38) 22(11-34) 0.98 
MV duration, days, median [IQR] 16 (11-29) 20(13-31) 0.04 
Appropriateness of ATB therapy (%) 147 (81.7%) 184(81.4%) 0.99 
Previous ATB (%) 72 (40.0%) 103 (45.6%) 0.27 
MDR pathogen (%) 69 (38.3%) 103 (45.6%) 0.16 
Basal serum CRP (median (IQR)) 163 (108-196) 168 (126-213) 0.77 
CRP maximum within 72h (median (IQR)) 168 (119-201) 179 (135-243) 0.30 
CRP at 96h (median (IQR)) 116 (81-165) 128 (83-178) 0.29 
 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range; LOS – length of stay; MV – mechanical ventilation; CRD – Chronic renal disease; COPD – 
chronic obstructive pulmonary disease; ATB – antibiotic therapy; CCI – chronic critical illness; MDR 
– multidrug resistant. 
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Table 2 – Etiology of VAP episodes in older and younger patients 
 
 ETIOLOGY Younger Older p 
Enterobacteriaceae 63 (26.0%) 59 (36.0%) 0.04 
                E. coli 4 (1.7%) 9 (5.5%)  
                Enterobacter spp. 19 (7.8%) 20 (12.2%)  
                 Klebsiella spp. 32 (13.2%) 23 (14.0%)  
                Other 
Enterobacteriaceae 
8 (3.3%) 7 (4.3%)  
S. aureus 41 (16.9%) 34 (20.7%) 0.40 
                  MSSA 34 (14.0%) 24 (14.6%)  
                  MRSA 7 (2.9%) 10 (6.1%)  
Pseudomonas aeruginosa 38 (15.7%) 31 (18.9%) 0.48 
Acinetobacter sp. 53 (21.9%) 35 (21.3%) 0.99 
Streptococcus pneumoniae 3 (1.2%) 2 (1.2%) 0.99 
Haemophilus influenzae 11 (4.5%) 2 (1.2%) 0.10 
Serratia sp. 12 (4.9%) 4 (2.4%) 0.30 
Stenotrophomonas 
maltophila 
15 (6.2%) 10 (6.1%) 0.99 
Polymicrobial episodes 63 (26.0%) 40 (24.4%) 0.80 
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Table 3. Comparison of characteristics between older and younger ICU patients   
 
  Younger Older p 
Number of patients                                  242     164  
Age (mean (SD))         45.6 (13.5) 73.6 (6.3) <0.001 
Gender (male/female) (%) 60.3/39.7% 62.2/37.8% 0.76 
APACHE II (mean (SD)) 19.1 (9.8) 23.8 (9.6) <0.001 
LOS MV before PAV (median [IQR]) 8 (5-13) 9 (6-14) 0.14 
Admission type (%)   0.03 
Medical                                                                                                                                                     158 (65.3%) 89 (54.3%)
Surgery 84 (34.7%) 75 (45.7%)  
Heart failure class IV (n (%)) 16 (6.6%) 22 (13.4%) 0.03 
AIDS (n (%)) 28 (11.6%) 1 (0.6%) <0.001 
Cirrhosis (n (%)) 25 (10.3%) 5 (3.0%) <0.001 
CRD (n (%)) 12 (5.0%) 15 (9.1%) 0.14 
Diabetes (n (%)) 32 (13.2%) 28 (17.1%) 0.35 
Hypertension (n (%)) 49 (20.2%) 64 (39.0%) <0.001 
Dementia (n (%)) 5 (2.1%) 12 (7.3%) 0.02 
Cancer (%) 48 (19.8%) 38 (23.2%) 0.49 
COPD (%) 11 (4.5%) 22 (13.4%) <0.001 
More than 2 Comorbidities (n (%))* 115 (47.5%) 110(67.1%) <0.001 
CCI (n (%)) 57 (23.6%) 42 (25.8%) 0.64 
ICU LOS, days, median [IQR] 21 (14-32) 24 (16-37) 0.04 
MV duration, days, median [IQR] 18 (12-29) 20 (12-31) 0.21 
Appropriateness of ATB therapy (%) 189 (78.1%) 142 (86.6%) 0.04 
Previous ATB (%) 96 (39.7%) 79 (48.2%) 0.10 
MDR pathogen (%) 96 (39.7%) 76 (46.3%) 0.18 
Basal serum CRP (median (IQR)) 167 (113-198) 164 (118-213) 0.49 
CRP maximum within 72h (median (IQR)) 175 (131-219) 168 (125-211) 0.64 
CRP at 96h (median (IQR)) 131 (83-173) 125 (85-165) 0.30 
ICU Mortality (n(%)) 119 (49.2%) 107 (65.2%) <0.001 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range; LOS – length of stay; MV – mechanical ventilation; CRD – Chronic renal disease; COPD – 
chronic obstructive pulmonary disease; ATB – antibiotic therapy; CCI – chronic critical illness. 
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Table 4. Comparison of CRP response according to age in ICU patients 
 
  Younger Older p 
CRUDE    
Basal serum CRP (mean (SD)) 164.9 (88.6) 173.1 (84.6) 0.51 
CRP maximum within 72h (mean (SD)) 184.0 (91.1) 177.2 (76.7) 0.59 
CRP at 96h (mean (SD)) 139.5 (84.6) 123.3 (63.2) 0.15 
CRP ratio (median [IQR]) 1.22 (0.84-1.67) 0.96 (0.70-1.25) 0.09 
ONLY APPROPRIATE ANTIBIOTIC THERAPY    
Basal serum CRP (mean (SD)) 166.6 (88.3) 174.8 (79.1) 0.52 
CRP maximum within 72h (mean (SD)) 185.5 (91.3) 178.8 (76.4) 0.60 
CRP at 96h (mean (SD)) 141.7 (85.5) 125.1 (64.0) 0.14 
CRP ratio (median [IQR]) 0.85 (0.61-1.15) 0.71 (0.47-0.96) 0.07 
ANALYSIS OF COVARIANCE – ESTIMATED 
MARGINS ADJUSTED BY BASAL CRP LEVELS 
   
CRP maximum within 72h (mean (95% CI)) 187.2 (180.0-194.5) 174.1 (165.0-182.7) 0.05 
CRP at 96h (mean (95%CI)) 142.3 (128.0-153.5) 122.0 (108.3-135.0) 0.07 
 
ICU – Intensive Care unit; CRP – C-reactive protein; SD – Standard deviation; IQR – Interquartile 
range 
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Figure 1. Age plotted agains Martingale residuals in VAP patients 
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Figure 2. Correlation between age and CRP levels in VAP patients 
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Figure 3. CRP evolution in older and younger patients with VAP 
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CONCLUSÕES 
 
 Em conclusão, nesta tese avaliamos uma coorte de pacientes com diagnóstico 
de pneumonia nosocomial em ventilação mecânica e a evolução da PCR em duas 
populações específicas, não avaliadas previamente na literatura.  
Descrevemos que pacientes que desenvolvem PAV num cenário de doença 
crítica crônica tem pior prognóstico, apresentando maior hazard risk para mortalidade 
na UTI após ajuste pra gravidade de doença na admissão, presença de patógenos 
multi-resistentes e comorbidades. Ainda, não encontramos uma alteração na cinética 
ou comprometimento na resposta inflamatória, medida pela evolução dos níveis de 
PCR, sugerindo que na população de pacientes com doença crítica crônica, o uso de 
PCR como um biomarcador da evolução dos pacientes permanence uma estratégia 
válida. 
De maneira análoga, avaliamos também os episódios de PAV em diferentes 
faixas etárias. Pacientes idosos que desenvolvem PAV tem pior prognóstico, com 
maior mortalidade, maior gravidade na admissão e mais comorbidades. O efeito no 
prognóstico parece iniciar a partir de 65 anos. Ainda, não encontramos diferença nos 
niveis de PCR ou na sua cinética, quando comparamos pacientes com diferentes 
faixas etárias (> ou <65 anos). Também não detectamos correlação entre a idade e os 
níveis de PCR, sugerindo que a PCR mantem suas características como biomarcador 
de evolução em pacientes com PAV, independente da faixa etária. 
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CONSIDERAÇÕES FINAIS 
 
 A pneumonia nosocomial permanece uma condição clínica prevalente com 
alta morbimortalidade associadas. Neste trabalho, revisamos diversos aspectos de sua 
epidemiologia, fisiopatologia, etiologia e manejo, além de levantar diversas áreas de 
incerteza na literatura.  
 Pudemos ainda avaliar, em dois estudos originais, o uso da proteína C-reativa 
(PCR) como marcador da evolução dos pacientes com pneumonia nosocomial 
associada a ventilação mecânica em duas populações previamente não estudadas na 
literatura. Nos pacientes com doença crítica crônica, condição cuja prevalência vem 
aumentando dramaticamente nas unidades de terapia intensiva, pudemos verificar que 
a despeito de um questionamento empírico sobre a viabilidade de manutenção da 
resposta inflamatória nestes pacientes, a produção e a cinética das primeiras 96h deste 
biomarcador não foram diferentes daqueles pacientes sem doença crítica crônica. Isso 
sugere que possíveis mudanças qualitativas e quantitativas da resposta inflamatória 
neste grupo de pacientes, associada ao possível “esgotamento” da capacidade de 
reação do sistema imunológico, não parecem afetar a PCR, permitindo seu uso na 
avaliação da evolução de eventos infecciosos nesta população. Além disso, a 
descrição das características dos pacientes com PAV nesta população não foi 
devidamente avaliado na literatura até então. 
 Uma segunda análise, avaliou o efeito da idade na evolução dos pacientes com 
pneumonia associada a ventilação mecânica, bem como seu efeito na evolução da 
PCR como marcador da resposta inflamatória nesses pacientes. Embora a idade, a 
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partir dos 65 anos, pareça ter um efeito na mortalidade dos pacientes com PAV, não 
houve alteração na resposta da PCR ou na sua cinética nas primeiras 96h quando 
comparamos pacientes com diferentes faixas etárias a partir de um ponto de corte de 
65 anos. Esta informação auxilia no manejo dos pacientes idosos, pois sugere que o 
uso da PCR como marcador da evolução dos pacientes com pneumonia parece válida 
e não parece ser afetada pelo fenômeno de “imunosenescencia” descrito em outros 
aspectos qualitativos e quantitativos da resposta inflamatória em idosos. 
 Nossos resultados, portanto, além de revisar e pontuar diversas áreas de 
incerteza na literatura e oportunidades de investigação, puderam também, de maneira 
original, esclarecer alguns aspectos do uso de biomarcadores, especificamente de 
PCR, em duas populações especiais que não haviam sido estudadas previamente. Isto 
permite que os estudos futuros que avaliem intervenções baseadas em biomarcadores 
em pacientes com pneumonia nosocomial possam levar em consideração estas 
populações de pacientes, dado o comportamento similar na evolução dos 
biomarcadores nestes subgrupos em comparação com a população geral de pacientes 
criticamente doentes. 
 Infelizmente, nesta amostra não foi possível avaliar outros biomarcadores 
como procalcitonina, limitando as conclusões apenas ao universo da PCR. 
 As perspectivas que se abrem a partir desta análise incluem testar intervenções 
baseadas na PCR nestes dois grupos de pacientes. Além disso, o uso de 
biomarcadores como a PCR para identificar potenciais candidatos a intervenções 
especificas é uma estratégia promissora descrita na literatura. Nossos dados podem 
contribuir para a generalização destas estratégias aos pacientes com doença critica 
crônica e idosos. 
 
